Comparison · NCT03512262-a8bb4b8c
Abaloparatide vs Placebo: Number of Participants With New Clinical Fractures
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Abaloparatide vs Placebo: Number of Participants With New Clinical Fractures. Trial comparisons, record NCT03512262-a8bb4b8c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03512262-a8bb4b8c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00671 | 0.00119 | 0.037 | wilson | |
| Risk in group 2 | 0.038 | 0.013 | 0.106 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0313 | -0.0993 | 0.00802 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.177 | 0.0187 | 1.67 | log | |
| Odds ratio, group 1 over group 2 | 0.171 | 0.0175 | 1.67 | log | |
| Number needed to treat, for one fewer participant with the outcome on Abaloparatide than on Placebo | 32 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Abaloparatide | Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen. | 1 | 149 | OG000 |
| Group 2 | Placebo | Participants self-administered daily doses of placebo SC using a single-participant, multiple-use, prefilled injection pen. | 3 | 79 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With New Clinical Fractures
- Description
- Radiological evaluations were performed to identify any new clinical fractures (occurring after the screening visit).
- Time frame
- Baseline through Month 12
- Population
- ITT Population: All participants randomized into the study.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
- NCT number
- NCT03512262
- Phases
- PHASE3
- Conditions
- Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
- Interventions
- Abaloparatide, Placebo
- Lead sponsor
- Radius Health, Inc.
- Results first posted
- 2023-04-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03512262?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03512262-a8bb4b8c